Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. Where is the data? Delayed and chronic irAE surveillance and management after cessation of ICIs: expert insights from SITC on survivorship care and the need for long-term data.Journal for immunotherapy of cancer · 2026
   Article
2. What new renal biomarkers tell us about renal physiology: Collection: physiology applied to ICU.Annals of intensive care · 2026
   Review
3. Urine proteomics defines an immune checkpoint-associated nephritis signature.Journal for immunotherapy of cancer · 2025
   Article

Corrections and comments

• Erratum for
  Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis.2023

Authors and funding

19 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as